SYnAbs

Executive Summary

SYnAbs is a Belgian biotechnology company founded in 2014 and headquartered in Liège, dedicated to discovering and developing therapeutic antibodies for autoimmune and inflammatory diseases. The company leverages a proprietary discovery platform to generate novel antibody candidates with potential for high specificity and favorable pharmacokinetics. Its pipeline targets key pathways in chronic inflammatory conditions, aiming to address unmet medical needs in areas such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. As a privately held, early-stage biotech, SYnAbs operates in a competitive landscape but differentiates itself through its technology and focus on novel epitopes. The company currently appears to be in the preclinical or early clinical stage, with no disclosed pipeline data publicly available. Its progress hinges on advancing lead candidates toward IND-enabling studies and initial clinical trials. While the platform shows promise, risks include early-stage development uncertainties, funding requirements, and regulatory hurdles. A potential partnership or licensing deal could provide validation and non-dilutive capital. Overall, SYnAbs represents an early-stage opportunity with a focused strategy, but its valuation and timeline remain speculative until further data emerge.

Upcoming Catalysts (preview)

• Q2 2027Initiation of first-in-human clinical trial for lead candidate40% success
• Q4 2026Presentation of preclinical proof-of-concept data at major conference60% success
• 2026-2027Announcement of strategic partnership or licensing deal for platform35% success